57.8 F
Fort Worth
Monday, November 23, 2020
Health Care FDA Designates Orphan Drug status for TechFW client Nanoscope Technologies

FDA Designates Orphan Drug status for TechFW client Nanoscope Technologies

Other News

A look at big issues on Supreme Court’s agenda

Some of the issues either already on the Supreme Court's docket when it begins its new session or likely to be before the justices...

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad rally Monday, clawing back much of...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors. But Tarrant...

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students home in droves and switched to...

Sight could come to those with damaged retinas thanks to Bedford-based Nanoscope Technologies, a SmartStart client of TechFW.

The company recently received Orphan Drug Designation from the U.S. Food & Drug Administration (FDA) for its use of optogenetics and its work on retinitis pigmentosa, also known as RP, which refers to a group of inherited diseases causing retinal degeneration.

“This is a very, very big deal and means their development will be fast-tracked through the FDA,” said Darlene Boudreaux, executive director of TechFW, in a news release. “It also has some considerable financial perks.” 

NanoScope Technologies, with 10 employees, was founded by Samarendra Mohanty, the president and Chief Scientific Officer.

The company is located in Bedford because “we received approval for a pre-clinical research lab, have excellent access to TechFW, the convenience of DFW International Airport and a large number of former Alcon employees in the area,” Mohanty said.

Sulagna Bhattacharya, the CEO/COO of Nanoscope Technologies, said Orphan Drug Designation adds seven years of marketing exclusivity, patent term extension, eligibility for special FDA grants, application fee discounts and major tax breaks on clinical development worth approximately $10 million.

The virus (VMCO) and laser (NOD) techniques bypass damaged cells and inject a gene into working cells in the retina. The gene produces a protein that is light sensitive, helping the ganglion and bipolar cells regain sight. According to the release, the market potential in the U.S. alone for the orphan indication (RP) is approximately 200,000 people.

Efficacy tests with rodents have been completed and no adverse effects have been noted thus far in large animal studies. Clinical trials will begin in 2018 and are expected to last 3-to-5 years.

Nanoscope Technologies’ science combines molecular biology, bio-medical optics, neuroscience and bio-medical engineering. Its research is funded by industry as well as NIH-SBIR’s and NEI’s Audacious Goal Initiative.

In addition to its work with restoration of vision, Nanoscope is testing its light-based technologies for non-invasive cancer detection and non-invasive chronic pain management.



Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox.

We don’t spam! Read our privacy policy for more info.

Latest News

These health care workers will be first in line for a COVID-19 vaccine

Health care workers will be the first people in Texas to receive a COVID-19 vaccine once one receives emergency approval from the U.S. government,...

Tarrant County reports 1,537 new COVID cases on Sunday and 6 deaths

Tarrant County Public Health reported 1,537 new cases on Sunday, Nov. 22 and six deaths. “It took 90 days to reach 10,000 cases in June....

Employers start sending workers shopping for health coverage

Instead of offering one or more options, some companies are turning health insurance shopping over to employees. A federal rule change last year stoked this...

E-commerce firm that acquired Pier 1, takes RadioShack assets

Look who is joining former Fort Worth home furnishing retailer Pier 1 Imports at e-commerce-focused business, Retail Ecommerce Ventures (REV): Fellow storied Fort Worth...

Abbott appoints Michael Coble to Texas Forensic Science Commission

Gov. Greg Abbott has appointed Michael Coble, Ph.D. to the Texas Forensic Science Commission for a term set to expire on Sept. 1, 2021. The...